"Teva will do everything in its power to protect our intellectual property," he said.
written on 02.05.2014
1Q EARNINGS: Teva, Mylan differ on generic Copaxone entry
Latest Reports
New Era in Access to Rare Disease Drugs in Canada
Durhane Wong-Rieger is the President & CEO of the Canadian Organization for Rare Disorders (CORD). In her first…
“Canada Needs to do Better in Supporting Innovative Biopharma”
Brian Hilberdink, President of Novo Nordisk Canada, calls for the Canadian government to encourage and invest in…
Success in Rare Disease Patient Advocacy — What it Takes
After her son was diagnosed with SYNGAP1 – an extremely rare gene mutation – Monica Weldon founded Bridge the…